CHROMOS ENTERS DEFINITIVE AGREEMENT TO ACQUIRE TARGETED MOLECULES AND SECURES FINANCING COMMITMENTS

Chromos Molecular Systems Inc. (TSX:CHR) announced today that it has entered into a definitive agreement under which it will acquire Targeted Molecules Corporation ("TMC"), a privately held San Diego based biotechnology company focused on the research and development of two antibody product candidates for treatment of multiple sclerosis (MS) and acute thrombosis. Concurrently with the acquisition Chromos will complete a private placement to raise not less than $6.0 million, the proceeds of which will be used to finance operations.

CNW Group (http://www.newswire.ca/en/releases/archive/October2005/26/c6392.html)